Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.
Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.
Scholtissen
B
B
Department of Psychiatry and Neuropsychology, Institute of Brain and Behaviour, Maastricht University, Maastricht, The Netherlands. b.scholtissen@np.unimaas.nl
Verhey
F R J
FR
Steinbusch
H W M
HW
Leentjens
A F G
AF
D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000706:statistics & numerical data; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012701:Serotonin / Q000378:metabolism*; D018490:Serotonin Agents / Q000627:therapeutic use
D018490:Serotonin Agents; D012701:Serotonin; D004298:Dopamine